---
title: "新锐医药国际控股有限公司 (06108.HK)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/06108.HK.md"
symbol: "06108.HK"
name: "新锐医药国际控股有限公司"
industry: "医疗产品分销商"
---

# 新锐医药国际控股有限公司 (06108.HK)

| Item | Detail |
|------|--------|
| Industry | 医疗产品分销商 |
| Location | 港股市场 |
| Website | [www.newraymedicine.com](https://www.newraymedicine.com) |

## Company Profile

新锐医药国际控股有限公司是一家主要从事医药分销贸易以及提供营销和推广服务的投资控股公司。该公司通过两个分部开展业务。医药及相关产品分销及贸易分部主要从事药品及医药化学试剂分销及贸易。提供营销及推广服务分部主要从事提供药品及医药化学试剂的营销及推广服务。该公司主要在中国国内市场开展业务。

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-21T04:30:11.000Z

**Overall: C (0.46)**

**Industry**: Health Care Distributors

| Metric | Value |
|--------|-------|
| Industry Ranking | 16 / 21 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 240.05% |  |
| Net Profit YoY | -166.48% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.11 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 44.94M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 121.93M |  |


**Multi Score**: C

#### Profit Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -7.70% | D |
| Profit Margin | -28.20% | E |
| Gross Margin | 8.13% | E |

#### Growth Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 240.05% | A |
| Net Profit YoY | -166.48% | E |
| Total Assets YoY | -9.68% | E |
| Net Assets YoY | -9.45% | D |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -354.66% | D |
| OCF YoY | 240.05% | A |

#### Operating Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.26 | D |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 5.12% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - 新锐医药国际控股有限公司",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "D",
      "indicators": [
        {
          "name": "ROE",
          "value": "-7.70%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-28.20%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "8.13%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "B",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "240.05%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-166.48%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-9.68%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-9.45%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-354.66%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "240.05%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "D",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.26",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "5.12%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | GUANZE MEDICAL (HK.2427) | B | A | C | A | B | B |
| 02 | 药师帮 (HK.9885) | C | B | A | D | B | B |
| 03 | 君百延集团 (HK.8372) | B | B | B | A | B | B |
| 04 | 上海医药 (HK.2607) | C | C | A | D | B | C |
| 05 | 白云山 (HK.874) | C | C | A | C | B | C |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.31 | 16/23 | - | - | - |
| PB | 0.11 | 1/23 | 0.15 | 0.15 | 0.12 |
| PS (TTM) | 0.37 | 11/23 | 0.77 | 0.55 | 0.40 |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview](https://longbridge.com/en/quote/06108.HK/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/06108.HK/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/06108.HK/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.